MedPath

Feasibility of ultra high field 7.0. Tesla MR Spectroscopy for breast cancer detection and monitoring of neo-adjuvant chemotherapy efficacy

Withdrawn
Conditions
breast cancer
breast neoplasm
10006288
Registration Number
NL-OMON35742
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

- 18 years or older
- Females
- Group 1: patients selected for neo-adjuvant chemotherapy
- Group 2: patients with BIRADS 4c or 5 classification on mammography, US or lower field MRI, selected for surgery
- Group 3: healthy volunteers

Exclusion Criteria

- Any prior surgery or radiotherapy to the ipsilateral breast
- Karnofsky score <= 70
- Pregnant or lactating women
- Contra-indications to MRI scanning according to the 7T screening list of the UMCU

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>1. Sensitivity of 7T MRS detection of histological proven breast cancer. The in<br /><br>vivo 7T MRS data will be compared to ex vivo measurements with HR-MAS and LC-MS.<br /><br>2. Sensitivity of 7T MRS to monitor neo-adjuvant chemotherapy effects in<br /><br>membrane metabolism </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>-</p><br>
© Copyright 2025. All Rights Reserved by MedPath